9:00am - 5:00pm

Office Hours Mon. - Fri.

800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Archive

Study of Carboplatin and Vinorelbine in Malignant Pleural Mesothelioma

Condition Malignant Pleural Mesothelioma Estimated Enrollment: 40 Age Group: 18 Years to 85 Years   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: MPM phase II Carbo/VNB Study First Received: January 3, 2006 Last Updated: September 17, 2009 Estimated Primary Completion Date: September 2009 Primary Outcome Measures: Response|Survival|Feasibility Sponsors and Collaborators: Rigshospitalet, Denmark Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT00272558...

Continue reading

Dendritic Cell-based Immunotherapy Combined With Low-dose Cyclophosphamide in Patients With Malignant Mesothelioma

Condition Malignant (Pleural) Mesothelioma Estimated Enrollment: 10 Age Group: Child, Adult, Senior Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: NL24050.000.08 Study First Received: June 1, 2010 Last Updated: February 26, 2014 Estimated Primary Completion Date: October 2011 Primary Outcome Measures: number of cytotoxic T cells and regulatory T cells in the blood of patients|safety and toxicity Sponsors and Collaborators: Erasmus Medical Center Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT01241682...

Continue reading

Pemetrexed Plus Gemcitabine or Carboplatin for Patients With Advanced Malignant Pleural Mesothelioma

Condition Mesothelioma Estimated Enrollment: 32 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: CDR0000401795|U10CA021115|E1B03 Study First Received: January 7, 2005 Last Updated: November 30, 2012 Estimated Primary Completion Date: September 2009 Primary Outcome Measures: Best Overall Response by RECIST Criteria (Version 1.0)|Overall Survival|Progression-Free Survival Sponsors and Collaborators: Eastern Cooperative Oncology Group|National Cancer Institute (NCI)|North Central Cancer Treatment Group Result Received: February 12, 2010 Website Link: https://ClinicalTrials.gov/show/NCT00101283...

Continue reading

Dendritic Cell-based Immunotherapy in Mesothelioma

Condition Malignant Pleural Mesothelioma Estimated Enrollment: 10 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: MEC-2005-269|PMR-MM05-001 Study First Received: January 20, 2006 Last Updated: November 15, 2010 Estimated Primary Completion Date: September 2009 Primary Outcome Measures: safety|tolerability Sponsors and Collaborators: Erasmus Medical Center Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT00280982...

Continue reading

Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) Versus Placebo in Advanced Malignant Pleural Mesothelioma (0683-014 AM5, EXT1)

Condition Mesothelioma|Lung Cancer Estimated Enrollment: 662 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Treatment Study ID Numbers: 0683-014|2005_010|CTRI/2009/091/000146 Study First Received: August 5, 2005 Last Updated: April 17, 2015 Estimated Primary Completion Date: July 2011 Primary Outcome Measures: Overall survival|Number of participants with adverse events characterized as Grade 3/4 according to the National Cancer Institute (NCI) Common Terminology for Adverse Events (CTCAE)|Progression-free survival|Objective response rate|Percent change from baseline in dyspnea score of the Lung Cancer Symptom Scale modified for mesothelioma (LCSS-Meso)|Percent change from baseline in forced vital capacity (FVC) Sponsors and Collaborators: Merck Sharp & Dohme Corp. Result...

Continue reading

Pemetrexed Plus Gemcitabine as Front-Line Chemotherapy for Patients With Malignant Pleural or Peritoneal Mesothelioma

Condition Mesothelioma Estimated Enrollment: 48 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: 7214|H3E-US-JMFZ Study First Received: May 28, 2003 Last Updated: January 24, 2007 Estimated Primary Completion Date: null Primary Outcome Measures: To determine the objective tumor response rate for pemetrexed plus gemcitabine every 21 days in patients with malignant pleural mesothelioma who have not received prior chemotherapy|To assess time to objective tumor response for responding patients;To assess duration of response for responding patients;To assess time to treatment failure;To assess time to progressive disease|To assess progression-free survival;To assess overall...

Continue reading

Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma

Condition Mesothelioma Estimated Enrollment: 53 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: AVF3442S Study First Received: February 22, 2006 Last Updated: November 4, 2016 Estimated Primary Completion Date: June 2010 Primary Outcome Measures: Progression Free Survival Rate at 6 Months|Response Rate|Overall Survival Sponsors and Collaborators: University of Texas Southwestern Medical Center|University of Chicago|Columbia University|Duke University Result Received: October 18, 2013 Website Link: https://ClinicalTrials.gov/show/NCT00295503...

Continue reading

An Open-label, Phase II Trial of ZD1839 (IRESSA) in Patients With Malignant Mesothelioma

Condition Mesothelioma Estimated Enrollment: 23 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: 1839IL/0094 Study First Received: November 6, 2008 Last Updated: June 5, 2012 Estimated Primary Completion Date: April 2008 Primary Outcome Measures: To assess the activity of ZD1839 in patients with malignant mesothelioma by estimating the objective response rate (CR and PR) at trial closure|To further characterize the safety profile of ZD1839 at a 250mg daily dose|To estimate PFS (progression free survival)|To estimate overall survival|To estimate duration of response Sponsors and Collaborators: AstraZeneca Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT00787410...

Continue reading

Survival of Peritoneal Mesothelioma After Cytoreductive Surgery and Hyperthermic Intra-peritoneal Chemotherapy (HIPEC)

Condition Peritoneal Mesotheliomas Estimated Enrollment: 19 Age Group: Child, Adult, Senior Gender: All Study Type: Observational Study Design Allocation: Observational Model: Case-Crossover|Time Perspective: Retrospective Study ID Numbers: Maisonneuve Rosemont Hospital|12112 Study First Received: March 12, 2013 Last Updated: March 15, 2013 Estimated Primary Completion Date: March 2013 Primary Outcome Measures: Overall survival|Disease-Free survival Sponsors and Collaborators: Maisonneuve-Rosemont Hospital Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT01812148...

Continue reading

Dasatinib in Treating Patients With Previously Treated Malignant Mesothelioma

Condition Malignant Mesothelioma Estimated Enrollment: 46 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: CALGB-30601|U10CA031946|CDR0000558362 Study First Received: July 30, 2007 Last Updated: July 11, 2016 Estimated Primary Completion Date: February 2010 Primary Outcome Measures: 24 Week Progression Free Survival|Number of Participants With Overall Tumor Response|Overall Survival|Progression Free Survival Sponsors and Collaborators: Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) Result Received: December 11, 2012 Website Link: https://ClinicalTrials.gov/show/NCT00509041...

Continue reading